These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 19095597

  • 1. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
    Davidson MB, Wong A, Hamrahian AH, Stevens M, Siraj ES.
    Endocr Pract; 2008 Nov; 14(8):985-92. PubMed ID: 19095597
    [Abstract] [Full Text] [Related]

  • 2. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 3. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M.
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [Abstract] [Full Text] [Related]

  • 4. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Heerspink HJL, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P, PRIORITY investigators.
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [Abstract] [Full Text] [Related]

  • 5. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor.
    Ogawa S, Takeuchi K, Mori T, Nako K, Ito S.
    Clin Exp Pharmacol Physiol; 2006 Apr; 33(5-6):477-9. PubMed ID: 16700881
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct 15; 78(8):902-7. PubMed ID: 8888663
    [Abstract] [Full Text] [Related]

  • 7. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
    Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD.
    J Am Soc Nephrol; 2009 Dec 15; 20(12):2641-50. PubMed ID: 19926893
    [Abstract] [Full Text] [Related]

  • 8. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A, Noshad S, Jarrah S, Mousavizadeh M, Khoee SH, Nakhjavani M.
    Nephrol Dial Transplant; 2013 Nov 15; 28(11):2823-33. PubMed ID: 24009294
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of aldosterone blockade in patients with diabetic nephropathy.
    Sato A, Hayashi K, Naruse M, Saruta T.
    Hypertension; 2003 Jan 15; 41(1):64-8. PubMed ID: 12511531
    [Abstract] [Full Text] [Related]

  • 10. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P.
    Diabet Med; 2012 Aug 15; 29(8):e184-90. PubMed ID: 22268920
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov 15; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus.
    Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C, Feldman K, Adler GK.
    J Clin Endocrinol Metab; 2007 Jul 15; 92(7):2552-8. PubMed ID: 17488800
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb 15; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 19. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Elajami TK, Alfaddagh A, Lakshminarayan D, Soliman M, Chandnani M, Welty FK.
    J Am Heart Assoc; 2017 Jul 14; 6(7):. PubMed ID: 28710178
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.